Nuvation Bio Stock Forecast
NYSE: NUVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
After hours: 4.95 0.00%
NUVB analyst consensus
Consensus (11 analysts)
strong_buy
Avg. price target
$13.00+162.63%
- Strong buy 3
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 11 Wall Street analysts covering Nuvation Bio (2026-10-07), 10 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $13.00, with a high estimate of $21.00 and a low estimate of $7.00. The average target implies upside of 162.6% from the current price of $4.95.
The spread between the highest and lowest targets is 200.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for NUVB.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 27% |
| Buy | 7 | 64% |
| Hold | 1 | 9% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $7.00 | +41.41% |
| Average target | $13.00 | +162.63% |
| High target | $21.00 | +324.24% |